A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Phase 1

DSP107A Study of Dual-SIgnaling Protein 107 (DSP107) for Patients With Hematological Malignancies

Sponsor:

Kahr Medical

Code:

NCT04937166

Conditions

Acute Myeloid Leukemia

Myelodysplastic Syndromes

Chronic Myelomonocytic Leukemia

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

DSP107

Azacitidine

Venetoclax

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-05-22. This information was provided to ClinicalTrials.gov by Kahr Medical on 2025-05-14.